[Irreversible nerve damages after herpes zoster oticus].
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005158:Facial Paralysis / Q000188:drug therapy / Q000209:etiology* / Q000628:therapy; D005260:Female; D006562:Herpes Zoster / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use; D010033:Otitis Media / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D010159:Palate; D010243:Paralysis / Q000188:drug therapy / Q000209:etiology; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy; D026741:Physical Therapy Modalities; D011239:Prednisolone / Q000627:therapeutic use; D013806:Theophylline / Q000627:therapeutic use; D013831:Thiamine / Q000627:therapeutic use; D014805:Vitamin B 12 / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D009539:Nicotinic Acids; D011239:Prednisolone; D013806:Theophylline; D014805:Vitamin B 12; D013831:Thiamine
Irreversible Nervenschäden nach Herpes zoster oticus.